LaCascia Michael 4

What Happened
Michael LaCascia, Chief Legal Officer of Foghorn Therapeutics (FHTX), was granted a derivative award on January 30, 2026 for 295,000 underlying shares with an exercise/strike price of $5.71, representing an aggregate contract value of $1,684,450. This filing reports a grant/award (transaction code A), not an open-market purchase or sale — it’s a compensation grant (stock option-style derivative), not an immediate cash transaction.

Key Details

• Transaction date: 2026-01-30; Form 4 filed 2026-02-02 (timely; within SEC filing window).
• Award: 295,000 underlying shares (derivative) with exercise price $5.71; aggregate value shown $1,684,450.
• Vesting (footnote F1): 25% vests on January 30, 2027, then 6.25% of underlying shares vest on the first day of each calendar quarter thereafter.
• Shares owned after transaction: Not specified in the provided filing extract.
• Transaction code: A (award/grant). No 10b5-1, tax-withholding, or immediate sale noted in the provided data.

Context
This was a compensation grant (derivative/option-style award) that vests over time; it does not indicate an exercised option or an immediate sale. Such grants are a routine part of executive compensation to align management with shareholders and should be viewed differently from outright purchases (which can be a stronger bullish signal).